|
1）UK prospecyive diabetes Study (UKPDS) Group: Effect of intensive blood–glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDES 34). Lancet. 1998; 352: 854-65
|
|
|
|
2）Zhou G, Myers R, Li Y, et al. Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest. 2001; 108: 1167-74
|
|
|
|
|
|
3）Kurth-Kraczek EJ, Hirshman MF, Goodyear LJ, et al. 5’ AMP-activated protein kinase activation causes GLUT4 translocation in skeletal muscle. Diabetes. 1999; 48: 1667-71
|
|
|
|
|
|
4）Fidan E, Onder Ersoz H, Yilmaz M, et al. The effects of rosiglitazone and metformin on inflammation and endothelial dysfunction in patients with type 2 diabetes mellitus. Acta Diabetol. 2011; 48: 297-302
|
|
|
|
|
|
5）Viollet B, Guigas B, Sanz Garcia N, et al. Cellular and molecular mechanisms of metformin: an overview. Clin Sci. 2012; 122: 253-70
|
|
|
|
|
|
6）Hou X, Song J, Li XN, et al. Metformin reduces intracellular reactive oxygen species levels by upregulating expression of the antioxidant thioredoxin via the AMPK-FOXO3 pathway. Biochem Biophys Res Commun. 2010; 396: 199-205
|
|
|
|
|
|
7）Song J, Ren P, Zhang L, et al. Metformin reduces lipid accumulation in macrophages by inhibiting FOXO1-mediated transcription of fatty acid-binding protein 4. Biochem Biophys Res Commun. 2010; 393: 89-94
|
|
|
|
|
|
8）Wang P, Kang D, Cao W, et al. Diabetes mellitus and risk of hepatocellular carcinoma: a system-atic review and meta-analysis. Diabetes Metab Res Rev. 2012; 28: 109-22
|
|
|
|
|
|
9）Libby G, Donnelly LA, Donnan PT, et al. New users of metformin are at low risk of incident cancer: a cohort study among people with type 2 diabetes. Diabetes Care. 2009; 32: 1620-5
|
|
|
|
|
|
10）DeCensi A, Puntoni M, Goodwin P, et al. Metformin and cancer risk in diabetic patients: a systematic review and meta-analysis. Cancer Prev Res. 2010; 3: 1451-61
|
|
|
|
|
|
11）Donadon V, Balbi M, Mas MD, et al. Metformin and reduced risk of hepatocellular carcinoma in diabetic patients with chronic liver disease. Liver Int. 2010; 30: 750-8
|
|
|
|
|
|
12）Jiralerspong S, Palla SL, Giordano SH. Metformin and pathologic complete responses to neoadju-vant chemotherapy in diabetic patients with breast cancer. J Clin Oncol. 2009; 27: 3297-302
|
|
|
|
|
|
13）Bowker SL, Majumdar SR, Veugelers P, et al. Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin. Diabetes Care. 2006; 29: 254-8
|
|
|
|
|
|
14）Jalving M, Gietema JA, Lefrandt JD, et al. Metformin: taking away the candy for cancer? Eur J Cancer. 2010; 46: 2369-80
|
|
|
|
|
|
15）Molinuevo MS, Schurman L, McCarthy AD, et al. Effect of metformin on bone marrow progenitor cell differentiation: in vivo and in vitro studies. Bone Miner Res. 2010; 25: 211-21
|
|
|
|
|
|
16）Jeyabalan J, Shah M, Viollet B, et al. AMP-activated protein kinase pathway and bone metabolism. J Endocrinol. 2012; 212: 277-90
|
|
|
|
|
|
17）Mai QG, Zhang ZM, Xu S, et al. Metformin stimulates osteoprotegerin and reduces RANKL expression in osteoblasts and ovariectomized rats. J Cell Biochem. 2011; 112: 2902-9
|
|
|
|
|
|
18） Borges JL, Bilezikian JP, Jones-Leone AR, et al. A randomized, parallel group, double-blind, multicentre study comparing the efficacy and safety of Avandamet (rosiglitazone/metformin) and metformin on long-term glycaemic control and bone mineral density after 80 weeks of treatment in drug-naïve type 2 diabetes mellitus patients. Diabetes Obes Metab. 2011; 13: 1036-46
|
|
|
|
|
|
19）Migoya EM, Bergeron R, Miller JL, et al. Dipeptidyl peptidase-4 inhibitors administered in combination with metformin result in an additive increase in the plasma concentration of active GLP-1. Clin Pharmacol Ther. 2010; 88: 801-8
|
|
|
|
|
|
20）Mulherin AJ. Mechanisms underlying metformin-induced secretion of glucagon-like peptide-1 from the intestinal L cell. Endocrinology. 2011; 152: 4610-9
|
|
|
|
|
|
21）Beisswenger PJ, Howell SK, Touchette AD, et al. Metformin reduces systemic methylglyoxal levels in type 2 diabetes. Diabetes. 1999; 48: 198-202
|
|
|
|
|
|
22）Rabbani N, Chittari MV, Bodmer CW, et al. Increased glycation and oxidative damage to apolipoprotein B100 of LDL cholesterol in patients with type 2 diabetes and effect of metformin. Diabetes. 2010; 59: 1038-45
|
|
|
|
|